Invo Fertility Inc

This management proposal requests stockholder approval to amend the Company’s Articles of Incorporation to increase authorized common shares from 50 million to 250 million (total authorized shares 350 million including preferred). Management frames the increase as necessary to permit conversion of Inducement Warrants (Proposal 4), to reserve 1,000,000 shares for the amended 2019 Stock Incentive Plan (Proposal 5), and to preserve flexibility to pursue financings, acquisitions, strategic partnerships, licensing, and equity-based compensation without the delay and expense of seeking subsequent stockholder approval. The Board emphasizes operational and capital-raising flexibility as the primary benefit, while acknowledging potential dilutive effects on existing holders and the lack of preemptive rights. The proposal would enable the company to issue shares for a variety of corporate purposes, which could both improve liquidity and capital resources but also create downward pressure on share price if large issuances occur. The Board retains discretion not to file the amendment even if approved, and notes that additional issuance decisions would remain subject to applicable laws and exchange rules. Stockholder approval requires a majority of votes cast; the Board recommends a “FOR” vote, stating the increase is in the best interests of the Company and stockholders to support near-term financing and operational goals. Investors should weigh the company’s immediate capital needs and planned transactions (including the inducement warrant conversion and plan reservation) against the dilution risk and potential impact on voting power and market perception.

This proposal asks stockholders to approve, under Nasdaq Listing Rule 5635(d), the issuance of common stock upon exercise of the Inducement Warrants (1,893,492 shares) and any additional shares that may become issuable under adjustment provisions in the warrants. Management entered an inducement letter to secure immediate cash exercise of existing warrants at a reduced price and to issue new unregistered warrants as consideration; Nasdaq approval is required because the resulting issuance may equal or exceed 20% of outstanding shares. The company has filed registration statements to permit resale and agreed to customary limitations (e.g., beneficial ownership conversion limits and restrictions on variable-rate transactions for a defined period). Board approval is being sought to satisfy Nasdaq rules, preserve the contractual inducement, and enable the Holder to exercise and resell warrants as registered. Important governance safeguards include a conversion blocker to prevent any holder from exceeding a specified ownership threshold and the requirement to register resale of the new warrant shares. Risks include significant potential dilution (warrant exercise, adjustment events) and downward pressure on market price when the underlying shares are sold; the Company highlights these risks in its risk-factor cross-references. The Board recommends approval as necessary to consummate the inducement arrangement, comply with Nasdaq listing requirements, and enable the financing and strategic objectives embodied in the Inducement Letter Agreement.

Management requests shareholder approval to increase the equity pool under the 2019 Stock Incentive Plan to 1,000,000 shares (about 20% on a fully-diluted basis). The company argues the larger reserve is needed to attract, retain and motivate employees, directors and consultants by aligning their interests with stockholders through options, stock awards and restricted stock. The Plan permits grants of options, stock awards and restricted stock, contains standard vesting and administration provisions, and allows annual increases up to 6% of outstanding shares through 2029 at the Plan administrator’s discretion. The Board and management note that directors and executive officers are eligible recipients, so insiders will benefit and have a material interest in the proposal. Key investor considerations include dilution from the increased reserve, potential impact on earnings per share, and the lack of preemptive rights for existing stockholders. Management recommends a FOR vote citing the need to preserve competitive compensation flexibility; stockholders should weigh anticipated hiring/retention benefits against dilution and governance protections (committee administration, adjustment provisions). Required vote is a majority of votes cast.

This proposal requests pre-approval under Nasdaq Listing Rule 5635(d) to enable the Company to effect financings that could result in issuances of 20,000,000 shares (up to $50 million in gross proceeds) or securities convertible into such shares within tightly defined parameters. Management says the authorization would allow committed equity facilities or private placements (including variable-priced facilities) to proceed without delay when market conditions or corporate needs make timing critical, subject to caps on share count, proceeds, maximum discount (20% general, 15% for certain facilities), commitment fees, a Floor Price equal to 20% of the Minimum Price, a three-month execution window following approval, and stated use of proceeds. The proposal is intended to comply with Nasdaq staff guidance (Interpretation Letter 2002-4) by setting maximums and a floor to render potential variable-priced issuances calculable for Nasdaq review. Key investor concerns include very large potential dilution (maximum share amount equals many times current outstanding shares), the risk of issuance at deep discounts relative to current trading, the use of Commitment Shares as fees (dilutive without cash proceeds), and the short execution window that may pressure decisions. The Board presents the authorization as a tool to preserve access to capital for working capital, acquisitions and clinic development while limiting extreme outcomes through defined caps; it unanimously recommends a FOR vote. Investors should consider the company's liquidity needs and the substantial potential dilution and market impact inherent in the maximum parameters when evaluating this proposal.

This proposal seeks a routine but important procedural authorization permitting the Board to adjourn or postpone the Annual Meeting to solicit additional proxies if there are insufficient votes to approve material proposals or to establish a quorum. Management argues this flexibility prevents unnecessary delays, allows additional outreach to holders (including the solicitation of broker votes), and helps ensure that the meeting can result in decisive outcomes on key corporate actions (director elections, auditor ratification, share authorizations, warrant approvals, plan amendment, and financing authorization). The authorization is time-limited to the meeting and only enables additional solicitation rather than modifying substantive proposals; it preserves stockholders’ ability to revoke prior proxies. Investors should recognize that adjournment powers can be used to seek votes again after close results, which could benefit management-supported outcomes; the Board discloses nominees’ interests in the result as relevant. The Board recommends a FOR vote to retain flexibility to achieve a quorum and obtain sufficient shareholder approval for the listed proposals.